Iovance Biotherapeutics Set to Announce Q4 Earnings on February 24
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy IOVA?
Source: seekingalpha
- Earnings Announcement: Iovance Biotherapeutics is set to release its Q4 earnings report on February 24 before the market opens, with investors keenly awaiting the results to gauge the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.18, indicating ongoing challenges in profitability that may affect investor confidence in the stock.
- Revenue Forecast: The revenue estimate is projected at $81.01 million, reflecting a 9.9% year-over-year growth, despite two downward revisions, suggesting sustained market demand for its products.
- Estimate Revisions: Over the past three months, EPS estimates have seen one upward revision with no downward adjustments, indicating a cautiously optimistic outlook from analysts regarding the company's future profitability, even as revenue estimates remain unchanged.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IOVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IOVA
Wall Street analysts forecast IOVA stock price to rise
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 3.745
Low
1.50
Averages
9.50
High
17.00
Current: 3.745
Low
1.50
Averages
9.50
High
17.00
About IOVA
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives on these companies.
- Market Dynamics Overview: While specific stocks are not detailed, changes in analyst ratings typically influence investor decisions and may lead to price fluctuations in the affected stocks.
- Investor Focus: For those considering buying U stock, analysts' opinions may provide crucial market insights, aiding them in making more informed investment choices.
- Source of Rating Changes: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, ensuring investors have access to comprehensive information to support their investment strategies.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these firms.
- ORCL Stock Outlook: Analysts have provided their latest views on ORCL stock for potential buyers, which could influence investor decisions and market sentiment regarding the stock.
- Market Dynamics Overview: The backdrop for these rating changes is a shifting market environment, with analysts evaluating based on the latest financial data and industry trends, indicating a cautious outlook on the overall market.
- Investor Focus: Investors should pay attention to these rating changes as they may impact stock price volatility and investment strategies for the affected companies, particularly in an uncertain economic climate.
See More
Iovance Biotherapeutics Reports Record Q4 Margins and Strong Upside Potential
- Record Quarterly Profit: Iovance reported Q4 revenue of $86.7 million, exceeding analyst expectations of $81 million, with gross margins rising from 43% in Q3 to 50%, demonstrating the effectiveness of operational optimization and indicating potential for future profitability improvements.
- Sales Growth: Total product revenue for Q4 reached approximately $87 million, a 30% increase from the previous quarter, with Amtagvi contributing around $65 million, highlighting strong market demand for this cell-based therapy in advanced melanoma treatment, which is expected to drive significant revenue growth for the company.
- FDA Fast Track Approval: Lifileucel received Fast Track designation from the FDA for previously treated nonsquamous non-small cell lung cancer, with preliminary data showing a 26% objective response rate, which will expedite its anticipated launch in the second half of 2027, further enhancing the company's competitive position in tumor immunotherapy.
- Extremely Bullish Market Sentiment: Retail investor sentiment for Iovance on Stocktwits was extremely bullish, with a 550% surge in message volume over 24 hours, reflecting strong confidence in the company's growth potential, which is likely to drive further stock price increases.
See More
Iovance Biotherapeutics Shares Surge on Positive Clinical Trial Data
- Clinical Trial Results: Iovance Biotherapeutics reported a 50% confirmed objective response rate (ORR) in a pilot trial for its TIL cell therapy among six evaluable patients, establishing a strong foundation for market opportunities in soft tissue sarcomas.
- Market Potential: With over 8,000 patients diagnosed annually in the U.S. and Europe with advanced undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma, Iovance's therapy is poised to address significant unmet medical needs, potentially driving future growth.
- Future Plans: The company intends to commence a single-arm registrational trial in Q2 2026 and engage with the FDA for expedited approval, demonstrating its proactive approach and confidence in the new therapy's potential.
- Stock Performance: Following the announcement, Iovance's shares surged by 29.41% to $3.74, reflecting strong investor enthusiasm for its clinical advancements, while aligning with the broader positive market trend.
See More
Iovance Biotherapeutics Q4 2025 Earnings Highlights
- Significant Revenue Growth: Iovance achieved a 30% revenue increase in Q4 2025, reaching $87 million, primarily driven by strong performance from Amtagvi, which not only enhances the company's market position but also lays a solid foundation for future expansion.
- Record Gross Margin: The gross margin improved from 43% in Q3 to 50% in Q4, indicating substantial progress in cost control and operational efficiency, thereby strengthening the company's profitability and financial stability.
- Robust Cash Position: By the end of 2025, Iovance reported a cash reserve of approximately $303 million, expected to sustain operations into Q3 2027, providing strong financial backing for commercial and clinical execution.
- FDA Fast-Track Designation: The company received FDA fast-track designation for lifileucel in non-small cell lung cancer and reported a 50% confirmed response rate in soft tissue sarcomas, which not only enhances the product's market potential but also offers a positive outlook for future clinical trials.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives on these companies.
- Market Dynamics Overview: While specific stocks are not detailed, changes in analyst ratings typically influence investor decisions and may lead to price fluctuations in the affected stocks.
- Investor Focus: For those considering buying U stock, analysts' opinions may provide crucial market insights, aiding them in making more informed investment choices.
- Source of Rating Changes: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, ensuring investors have access to comprehensive information to support their investment strategies.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these firms.
- ORCL Stock Outlook: Analysts have provided their latest views on ORCL stock for potential buyers, which could influence investor decisions and market sentiment regarding the stock.
- Market Dynamics Overview: The backdrop for these rating changes is a shifting market environment, with analysts evaluating based on the latest financial data and industry trends, indicating a cautious outlook on the overall market.
- Investor Focus: Investors should pay attention to these rating changes as they may impact stock price volatility and investment strategies for the affected companies, particularly in an uncertain economic climate.
See More
Iovance Biotherapeutics Reports Record Q4 Margins and Strong Upside Potential
- Record Quarterly Profit: Iovance reported Q4 revenue of $86.7 million, exceeding analyst expectations of $81 million, with gross margins rising from 43% in Q3 to 50%, demonstrating the effectiveness of operational optimization and indicating potential for future profitability improvements.
- Sales Growth: Total product revenue for Q4 reached approximately $87 million, a 30% increase from the previous quarter, with Amtagvi contributing around $65 million, highlighting strong market demand for this cell-based therapy in advanced melanoma treatment, which is expected to drive significant revenue growth for the company.
- FDA Fast Track Approval: Lifileucel received Fast Track designation from the FDA for previously treated nonsquamous non-small cell lung cancer, with preliminary data showing a 26% objective response rate, which will expedite its anticipated launch in the second half of 2027, further enhancing the company's competitive position in tumor immunotherapy.
- Extremely Bullish Market Sentiment: Retail investor sentiment for Iovance on Stocktwits was extremely bullish, with a 550% surge in message volume over 24 hours, reflecting strong confidence in the company's growth potential, which is likely to drive further stock price increases.
See More
Iovance Biotherapeutics Shares Surge on Positive Clinical Trial Data
- Clinical Trial Results: Iovance Biotherapeutics reported a 50% confirmed objective response rate (ORR) in a pilot trial for its TIL cell therapy among six evaluable patients, establishing a strong foundation for market opportunities in soft tissue sarcomas.
- Market Potential: With over 8,000 patients diagnosed annually in the U.S. and Europe with advanced undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma, Iovance's therapy is poised to address significant unmet medical needs, potentially driving future growth.
- Future Plans: The company intends to commence a single-arm registrational trial in Q2 2026 and engage with the FDA for expedited approval, demonstrating its proactive approach and confidence in the new therapy's potential.
- Stock Performance: Following the announcement, Iovance's shares surged by 29.41% to $3.74, reflecting strong investor enthusiasm for its clinical advancements, while aligning with the broader positive market trend.
See More
Iovance Biotherapeutics Q4 2025 Earnings Highlights
- Significant Revenue Growth: Iovance achieved a 30% revenue increase in Q4 2025, reaching $87 million, primarily driven by strong performance from Amtagvi, which not only enhances the company's market position but also lays a solid foundation for future expansion.
- Record Gross Margin: The gross margin improved from 43% in Q3 to 50% in Q4, indicating substantial progress in cost control and operational efficiency, thereby strengthening the company's profitability and financial stability.
- Robust Cash Position: By the end of 2025, Iovance reported a cash reserve of approximately $303 million, expected to sustain operations into Q3 2027, providing strong financial backing for commercial and clinical execution.
- FDA Fast-Track Designation: The company received FDA fast-track designation for lifileucel in non-small cell lung cancer and reported a 50% confirmed response rate in soft tissue sarcomas, which not only enhances the product's market potential but also offers a positive outlook for future clinical trials.
See More
